The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is a common complication of antibiotic therapy that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota and CDI recurrence. Two multinational trials were conducted to compare the efficacy of tolevamer, a nonantibiotic, toxin-binding polymer, with vancomycin and metronidazole. METHODS: Patients with CDI were randomly assigned in a 2:1:1 ratio to oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days, vancomycin 125 mg every 6 hours for 10 days, or metronidazole 375 mg every 6 hours for 10 days. The primary endpoint was clinical success, defined as resolution of diarrhea and absence of severe abdominal discomfort for more than 2 consecutive days including day 10. RESULTS: In a pooled analysis, 563 patients received tolevamer, 289 received metronidazole, and 266 received vancomycin. Clinical success of tolevamer was inferior to both metronidazole and vancomycin (P < .001), and metronidazole was inferior to vancomycin (P = .02; 44.2% [n = 534], 72.7% [n = 278], and 81.1% [n = 259], respectively). Clinical success in patients with severe CDI who received metronidazole was 66.3% compared with vancomycin, which was 78.5%. (P = .059). A post-hoc multivariate analysis that excluded tolevamer found 3 factors that were strongly associated with clinical success: vancomycin treatment, treatment-naive status, and mild or moderate CDI severity. Adverse events were similar among the treatment groups. CONCLUSIONS: Tolevamer was inferior to antibiotic treatment of CDI, and metronidazole was inferior to vancomycin. Trial Registration. clinicaltrials.gov NCT00106509 and NCT00196794.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Self-citationWarny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020
Emergence of Clostridium difficile-associated disease in North America and Europe
Kuijper, E. J., Coignard, B., & Tüll, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01580.x · Cited by 855
Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031
McDonald, L. C., Owings, M., & Jernigan, D. B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1203.051064 · Cited by 788
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
Self-citationCornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., Sears, P., & Gorbach, S. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70374-7 · Cited by 761
Self-citationIncreasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A. M., & Graninger, W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.813 · Cited by 505
Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole
Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., & Hamill, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430311 · Cited by 504
Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F., & Mascola, L. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1309.061116 · Cited by 429
Bauer, M. P., Kuijper, E. J., & van Dissel, J. T. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03099.x · Cited by 366
Mullane, K. M., Miller, M. A., Weiss, K., Lentnek, A., Golan, Y., Sears, P. S., Shue, Y.-K., Louie, T. J., & Gorbach, S. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir404 · Cited by 245
Self-citationC. difficile Infection: Changing Epidemiology and Management Paradigms
Vindigni, S. M., & Surawicz, C. M. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.24 · Cited by 234
Louie, T. J., Peppe, J., Watt, C. K., Johnson, D., Mohammed, R., Dow, G., Weiss, K., Simon, S., John, J. F., Garber, G., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/506349 · Cited by 203
Self-citationLouie, T. J., Emery, J., Krulicki, W., Byrne, B., & Mah, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-07 · Cited by 190
Self-citationWilcox, M. H., & Howe, R. A. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.4.673 · Cited by 122
Factors Associated With Failure of Metronidazole in Clostridium difficile–associated Disease
Fernandez, A. A., Anand, G., & Friedenberg, F. K. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200405000-00005 · Cited by 111
Cheknis, A. K., Sambol, S. P., Davidson, D. M., Nagaro, K. J., Mancini, M. C., Hidalgo-Arroyo, G. A., Brazier, J. S., Johnson, S., & Gerding, D. N. (2009) · Anaerobe · doi:10.1016/j.anaerobe.2009.09.001 · Cited by 61
Self-citationHinkson, P. L., Dinardo, C., DeCiero, D., Klinger, J. D., & Barker, R. H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00041-08 · Cited by 42
Clostridium difficile Outbreak Strain BI Is Highly Endemic in Chicago Area Hospitals
Black, S. R., Weaver, K. N., Jones, R. C., Ritger, K. A., Petrella, L. A., Sambol, S. P., Vernon, M. O., Burton, S., Garcia‐Houchins, S., Weber, S. G., et al. (2011) · Infection Control and Hospital Epidemiology · doi:10.1086/661283 · Cited by 29
Self-citation
Cited by
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Self-citationClostridium difficile Infection
Leffler, D. A., & Lamont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,450
Clostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
Dickey, S. W., Cheung, G. Y. C., & Otto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.23 · Cited by 799
Clostridium difficile infection: review
Czepiel, J., Dróżdż, M., Pituch, H., Kuijper, E. J., Perucki, W., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A., & Biesiada, G. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03539-6 · Cited by 702
Metadata
- Authors
- Johnson, S., Louie, T. J., Gerding, D. N., Cornely, O. A., Chasan-Taber, S., Fitts, D., Gelone, S. P., Broom, C., Davidson, D. M., & for the Polymer Alternative for CDI Treatment (PACT) investigators
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-05-05
- Volume
- 59
- Issue
- 3
- Pages
- 345-354
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2131038214
- Cited by
- 527
- References
- 27
- FWCI
- 30.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.